2012032
print

Hereditary Cancer Panel, Sequencing and Deletion/Duplication

CANCERPAN
Example Reports
Negative
Positive

Icon

Hereditary Cancer Testing Patient History Form

Icon

Informed Consent for Genetic Testing (Required for NY patients)

Icon

Additional Technical Information

Ordering Recommendation

Recommended test to confirm a hereditary cause of cancer in individuals with a personal or family history consistent with features of more than one cancer syndrome. Testing minors for adult-onset conditions is not recommended; testing will not be performed in minors without prior approval. For additional information, please contact an ARUP genetic counselor at 800-242-2787 ext. 2141.

To compare this test to other hereditary cancer panels, refer to the Hereditary Cancer Panel Comparison table.

New York DOH Approval Status

Testing is not New York state approved. Specimens from New York clients will be sent out to a New York state-approved laboratory.

Specimen Required

Patient Preparation
Collect

Lavender or pink (EDTA) or yellow (ACD solution A or B).

Specimen Preparation

Transport 3 mL whole blood. (Min: 2 mL)

Storage/Transport Temperature

Refrigerated

Unacceptable Conditions

Serum or plasma; grossly hemolyzed or frozen specimens; saliva, buccal brush, or swab; FFPE tissue; DNA.

Remarks
Stability

Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable

New York State Clients: Preferred Ambient: 4 days; Refrigerated: 4 days; Frozen: 4 days
It is preferred that specimens be received within 4 days of collection. Extraction will be attempted for specimens received after 4 days, and DNA yield will be evaluated to determine if testing may proceed.

Methodology

Massively Parallel Sequencing / Sequencing / Multiplex Ligation-Dependent Probe Amplification (MLPA)

Performed

Varies

Reported

14-21 days

Reference Interval

By report

Interpretive Data

Refer to report.

Compliance Category

Laboratory Developed Test (LDT)

Note

Genes Tested: ALK; APC*; ATM; AXIN2; BAP1; BARD1; BMPR1A*; BRCA1*; BRCA2; BRIP1; CDC73; CDH1*; CDK4; CDKN1B; CDKN2A*; CHEK2*; CTNNA1*; DICER1; EGFR; EPCAM**; FH; FLCN*; HOXB13; HRAS; KIT; LZTR1; MAX; MC1R; MEN1*; MET; MITF*; MLH1; MLH3*; MSH2; MSH3; MSH6; MUTYH; NBN; NF1; NF2; NTHL1; PALB2; PDGFRA*; PMS2; POLD1; POLE; POT1; PRKAR1A; PTCH1; PTEN*; RAD51C; RAD51D; RB1*; RECQL*; RET; SDHA*; SDHAF2; SDHB; SDHC*; SDHD*; SMAD4; SMARCA4; SMARCB1; SMARCE1*; STK11; SUFU; TERT; TMEM127; TP53; TSC1; TSC2; VHL*; WT1

*- One or more exons are not covered by sequencing and/or deletion/duplication analysis for the indicated gene; see Additional Technical Information.
**- Deletion/duplication analysis of EPCAM (NM_002354) exon 9 only, sequencing is not available for this gene.

Hotline History

View Hotline History

 

Hotline History

Date of Change
Test Name Change
Methodology
Performance/Reported Schedule
Specimen Requirements
Reference Interval
Interpretive Data
Note
CPT Code
Component Change
Other Interface Change
New Test
Inactive
10/06/2025
X
X
N/A

CPT Codes

81162; 81201; 81292; 81295; 81298; 81307; 81317; 81321; 81351; 81403; 81404; 81405; 81406; 81407; 81408; 81479

Are you an ARUP Client? Click here for your pricing.

Components

Component Test Code* Component Chart Name LOINC
2012033 Cancer Panel, Hereditary, Spcm 31208-2
2012034 Cancer Panel, Hereditary, Interp 35474-6
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • Birt-Hogg-Dube (BHD) syndrome
  • Coffin-Siris syndrome
  • Cowden syndrome
  • Familial Adenomatous Polyposis (FAP)
  • HBOC syndrome
  • Hereditary Diffuse Gastric Cancer (HDGC)
  • Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) syndrome
  • Hereditary Nonpolyposis Colorectal Cancer (HNPCC)
  • Hereditary Papillary Renal Carcinoma (HPRC) syndrome
  • Hereditary Paraganglioma Pheochromocytoma
  • Juvenile Polyposis syndrome (JPS)
  • Li-Fraumeni syndrome (LFS)
  • Lynch syndrome
  • Malignant Mesothelioma
  • MUTYH-Associated Polyposis (MAP)
  • Peutz-Jegher syndrome (PJS)
  • PTEN Hamartoma Tumor syndrome
  • Rhabdoid Tumor Predisposition syndrome
  • Tuberous Sclerosis Complex (TSC)
  • Von Hippel Lindau (VHL) syndrome
  • Wilms Tumor
Hereditary Cancer Panel, Sequencing and Deletion/Duplication